Verve Therapeutics, Inc. (VERV)

Market Cap	385.22M
Revenue (ttm)	24.40M
Net Income (ttm)	-197.03M
Shares Out	84.66M
EPS (ttm)	-2.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,412,288
Open	4.840
Previous Close	4.840
Day's Range	4.480 - 4.840
52-Week Range	4.305 - 19.340
Beta	1.76
Analysts	Strong Buy
Price Target	25.75 (+465.93%)
Earnings Date	Nov 5, 2024

About VERV

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company’s lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 2021
• Employees: 255
• Stock Exchange: NASDAQ
• Ticker Symbol: VERV
• Website: https://www.vervetx.com

Financial Performance

In 2023, Verve Therapeutics's revenue was $11.76 million, an increase of 505.77% compared to the previous year's $1.94 million. Losses were -$200.07 million, 27.1% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for VERV stock is "Strong Buy." The 12-month stock price forecast is $25.75, which is an increase of 465.93% from the latest price.

Price Target

$25.75

(465.93% upside)

Analyst Consensus: Strong Buy